| |
Software Requirements
Microsoft Internet Explorer 5.01 or higher and Netscape Navigator 4.75 or higher are recommended. |
|
 |
J.Health Sci., 51(6), 693-701, 2005
Simultaneous Chiral Analysis of Methamphetamine and its Metabolites by Capillary Electrophoresis/Mass Spectrometry with Direct Injection of Urine
Reiko Iio,*, a, b Satoshi Chinaka,a Nariaki Takayama,a and Kazuichi Hayakawab
aForensic Science Laboratory, Ishikawa Prefectural Police Headquarters, 1-1 Kuratsuki, Kanazawa 920-8553, Japan and bGraduate School of Natural Science and Technology, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
We describe a rapid and simple method for the analysis of the d- and l-isomers of seven methamphetamine-related compounds and the d-isomer of pseudoephedrine (pseudoEP) by capillary electrophoresis/mass spectrometry (CE/MS) with direct injection of urine. The compounds were methamphetamine (MA), amphetamine (AP), dimethylamphetamine, ephedrine, norephedrine, methylephedrine, p-hydroxymethamphetamine (pOHMA). The electrolyte was 1 M formic acid/1 M ammonium formate (10/0.2, v/v) (pH 2.0) containing 1.5 mM heptakis-(2,6-diacetyl-6-sulfato)-beta-cyclodextrin. The 14 enantiomers and d-pseudoEP were completely separated within 30 min. A urine sample was mixed with an equal volume of internal standard solution, filtered with a 0.45 mu m filter and then injected into the CE/MS system. In an analysis of urine sample from a healthy person spiked with racemic MA and AP, the reproducibilities (n = 6) of the migration times and peak areas after correction by an internal standard were under 0.08% and under 3.6%, respectively. The detection limits using selected ion monitoring were 0.01 mu g/ml (which corresponds to 0.02 mu g/ml urine) for the enantiomers of MA, AP and pOHMA. The detection yields of the enantiomers of MA, AP and pOHMA from urine were in the range of 97.7-108.8%. The proposed method was successfully used for the chiral analysis of urine samples from MA and dimethylamphetamine (DMA) addicts and patients under selegiline pharmacotherapy.
|
|
